(BioNTech) Shares of BioNTech rose 6% on Wed. as the company announced a net profit of 3.166 billion euros in the fourth quarter of 2021, from 366.9 million euros in the prior year.
The incomes of BioNTech were derived from a robust revenue of 5.533 billion euros in the fourth quarter, compared to $355.4 million euros in the prior year.
For FY21, BioNTech net profit hit 10.293 billion euros, up from only 15.2 million euros in the comparable quarter of 2020. FY21 revenues were 18.976 billion euros, from 482.3 million euros in 2020.
BioNTech diluted earnings per share was 12.18 euros in the fourth quarter, up from 1.43 euros per share in the prior year quarter. FY21 EPS was 39.63 euros, compared to just 0.06 euros in FY20.
The company said it expects to authorize up to $1.5 billion share repurchases over the next two years. The company also plans to propose a cash dividend of 2 euros per share.
BioNTech said that it delivered about 2.6 billion Covid-19 doses to more than 165 countries globally.
The company upheld its guidance for vaccine revenues of 13 billion euros to 17 billion euros in 2022.
BNTX: NASDAQ is up +6.76%
